A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects
Phase 2
3 Years
11 Years
3 Years
11 Years
Not Enrolling
Both
Warts
Both
Warts
Trial Information
A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects
Inclusion Criteria:
- Diagnosis of common wart(s)
- Ages between 3 to 11
Exclusion Criteria:
- Other types of wart(s), ie. plantar
- Currently participating in another clinical study
- Chronic viral hepatitis B or C
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment
Outcome Measure:
Clearance of treated common wart(s)
Authority:
United States: Food and Drug Administration
Study ID:
1534-RESI
NCT ID:
NCT00116662
Start Date:
March 2005
Completion Date:
Related Keywords:
- Warts
- Wart(s)
- Common Wart(s)
- Children
- Pediatric
- 3M Pharmaceuticals
- Resiquimod
- Warts
Name | Location |
|---|---|
| Arkansas | Fayetteville, Arkansas 72703 |
| Georgia | Newnan, Georgia 30263 |
| Illinois | Buffalo Grove, Illinois 60089 |
| Indiana | Lafayette, Indiana 47904 |
| Kansas | Wichita, Kansas 67207 |
| Massachusetts | Boston, Massachusetts 02114 |
| Missouri | St. Louis, Missouri 63110 |
| Utah | Layton, Utah 84041 |
| Vermont | Burlington, Vermont 05401 |
